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Abstract 
Background: Anaplastic thyroid cancers (ATC) represent only 1-2% of all thyroid tumors, but they 
account for up to 50% of the mortality. Treatment of differentiated thyroid carcinomas is well 
standardized and the use of radioiodine represents an essential step; in contrast, there is no 
standardized therapeutic approach for anaplastic tumors and their prognosis is poor. The resistance 
of anaplastic thyroid cancer to radioiodine treatment is principally due to the absence of expression 
of the sodium iodide symporter (NIS), mainly due to epigenetic silencing. The acetylation status of 
histones is involved in the epigenetic control of gene expression and is usually disrupted in 
advanced thyroid cancer. Histone deacetylase inhibitors have been demonstrated as potent 
anticancer drugs with several different effects on cell viability and differentiation.  
Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary 
cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with 
the histone deacetylase inhibitor LBH589. After treatment, we evaluated the expression and 
function of NIS. Gene expression was evaluated by real-time PCR (RT-PCR); NIS promoter 
activity was determined with a luciferase reporter assay; and protein expression was assessed 
through immunofluorescence. We tested the protein function by 125I uptake and efflux experiments; 
finally the cytotoxic effect of 131I was determined with a clonogenic assay.  
Results: Our results demonstrate that treatment with LBH589 leads to NIS RNA expression as 
shown by RT-PCR and luciferase assay, and to protein expression as determined by 
immunofluorescence in vitro and by immunohistochemistry in xenograft tumors. Moreover, 125I 
uptake and efflux experiments show the correct protein function and iodine retention, that translate 
into cytotoxicity effects, as demonstrated by a clonogenic assay with 131I .  
Conclusions: This study supplies a new potential strategy  for the treatment of ATC by modifying 
gene expression with the aim of inducing responsiveness towards radioiodine therapy. 
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Introduction 
Anaplastic thyroid carcinoma (ATC), despite its low incidence, is one of the most lethal human 
malignancies, accounting for about 50% of all thyroid carcinoma deaths (1, 2). Patients with ATC 
have a median survival of 3-5 months (2) even in the absence of metastasis at the time of diagnosis. 
At present, therapies available for ATC include chemotherapy, radiotherapy and surgery, but the 
outcomes are very poor; hence, there is a need for  new therapeutic strategies. 
Epigenetic alterations, which in the “epigenetic progenitor model” (3) are considered to be equally 
if not more important than mutational events for cancerogenesis, led to the concept of epigenetic 
therapy. Indeed, there is a strong basis for the use of “epigenetic modifier drugs” to modulate the 
epigenome of cancer cells to a status resembling the one seen in normal cells, thereby leading to 
tumor cell death or restoration of normal differentiation (4).   
The presence of the sodium iodide symporter (NIS) is both a diagnostic and a therapeutic tool in the 
management of thyroid cancer due to its ability of mediating iodide uptake (5). Unfortunately, 
approximately 10–20% of thyroid tumors comprising metastatic differentiated thyroid carcinomas, 
as well as poorly differentiated and anaplastic cancers (6), fail to uptake radioiodine and are unable 
to concentrate enough 131I for effective cytotoxic therapy; tumors with reduced or absent NIS 
activity are therefore generally associated with a poor prognosis. 
Deacetylase inhibitors (DCI) are compounds that are able to alter the chromatin acetylation status, 
modulating the transcription of about 2% of genes involved in growth, differentiation and apoptosis 
(7). NIS gene silencing has been related to histone acetylation. The use of DCI like trichostatin A 
(TSA), sodium butyrate (NaB) and valproic acid restored NIS expression in human thyroid cancer 
cell lines (8-10). Moreover, increased NIS expression was demonstrated in non-thyroid cell lines 
after treatment with TSA, NaB (10) and LBH589 (11). As far as ATC is concerned, we have 
reported elsewhere that valproic acid increased NIS expression in poorly differentiated thyroid 
cancer cell lines (9), but the effect of the drug in ATC is limited to mRNA expression without any 
consequence on iodine uptake. Panobinostat or LBH589 is a potent pan-deacetylase inhibitor with 
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anti-cancer activity as demonstrated in vitro against classical Hodgkin’s lymphoma (cHl), and in 
clinical phase I and phase II trials in patients with relapsed cHl (12). We recently demonstrated that 
LBH589 affects histone acetylation and has potent cytotoxic and anti-invasive activities in in vitro 
and in vivo ATC (13,14). 
The aim of the present work is the evaluation of LBH589 ability to induce NIS expression and 
activity in ATC  in order to obtain significant radioiodine uptake and sensitivity . 
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Materials and methods  
Cell lines and reagents 
Anaplastic thyroid carcinoma (BHT-101 and CAL-62) cell lines were purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany). Both cell lines were 
maintained at 37°C, in 5% CO2 and 95% humidity, in D-MEM-F12 (Invitrogen, Groningen, The 
Netherlands), with 100 IU/ml penicillin and 100 µg/ml streptomycin added, supplemented with 
10% heat inactivated FCS (Euroclone, Wetherby, West York, UK). LBH589 was provided by 
Novartis Pharma AG (Basel, Switzerland), prepared as a 5mM stock solution in DMSO and stored 
at -80°C. 
Primary culture establishment 
Anaplastic thyroid carcinoma samples were obtained from 7 patients undergoing thyroidectomy for 
ATC (cultures were labeled CPa-g). Samples obtained from two healthy thyroids were used as 
controls (labeled CPS1 and CPS2). Informed consent for the study was obtained from each patient. 
Tissues were obtained under sterile conditions and processed within 24 hours of surgery. Samples 
were washed three times in saline containing penicillin/streptomycin and nystatin and then minced 
in D-MEM-F12 and incubated overnight with 0.25% trypsin at 4°C. After this, enzymatic digestion 
was performed using 0.35% collagenase (Sigma, Milano, Italy) at 37°C for 60 min. Cells were 
filtered through double layers of sterile gauze and washed twice with D-MEM-F12 plus 20% FCS. 
Cells were cultured in complete medium containing 100 IU/ml penicillin and 100 µg/ml 
streptomycin, 50µg/ml gentamicin, 2.5µg/ml amphotericin B and 20% FCS.  
Primary cultures were tested for cytokeratins by immunofluorescence (monoclonal Anti-pan 
Cytokeratin Clone C-11, Sigma, Milano, Italy); and for thyroglobulin (Tg), Thyroid Transcription 
Factor 1 (TTF-1) and NIS expression by RT-PCR. All the cultures showed complete concordance 
with the original tumors or normal thyroid tissues (Table 1). 
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Gene expression evaluation with RT- PCR  
Cells (1x106) were seeded in 75cm2 flasks and treated with increasing doses of LBH589 (0 - 50 
nM). After 24 hours of treatment, total RNA was extracted using TRIzol Reagent (Invitrogen Ltd, 
Paisley, UK). DNase I was added to remove remaining genomic DNA. 1 µg of total RNA was 
reverse-transcribed with iScript cDNA Synthesis Kit (BioRad Laboratories, Inc.), following the 
manufacturer’s protocol. Primers (Table 2) were designed using Beacon Designer 5.0 software 
according to parameters outlined in the BioRad iCycler Manual. The specificity of the primers was 
confirmed by BLAST analysis. RT-PCR was performed using a BioRad iQ iCycler Detection 
System (BioRad Laboratories, Inc.) with SYBR green fluorophore. Reactions were performed in a 
total volume of 25 µl containing 12.5 µl IQ SYBR Green Supermix (BioRad Laboratories, Inc.), 1 
µl of each primer at 10 nM concentration, and 5 µl of the previously reverse-transcribed cDNA 
template. The protocol for each primer set was optimized using seven serial 5X dilutions of 
template cDNA obtained from cells in basal conditions. The protocol used was as follows: 
denaturation (95°C for 5 min), and 40 cycles of amplification (95°C for 15 sec, 60°C for 30 sec). A 
melting curve analysis was performed following every run to ensure a single amplified product for 
every reaction. For each sample all the reactions were carried out at least in triplicate. Results were 
normalized using the geometric mean for three different housekeeping genes (β-actin, β2-
microglobulin and L13A) and expressed as relative expression fold versus the lower level of 
expression. 
NIS Promoter Luciferase Assay 
Cells (2.5 x 105) were seeded in 6-well plates. 24 hours after seeding, cells were transfected with 1 
µg of NIS-luc plasmid/well using Lipofectin Reagent (Invitrogen Ltd, Paisley, UK). The plasmid, 
donated by Prof. G. Damante (Dipartimento di Scienze & Tecnologie Biomediche, Policlinico 
Universitario di Udine, Udine) contained 2.2 kb of 5' genomic sequence of the NIS promoter linked 
to the luciferase (LUC) gene as reporter (15). After 24 hours, cells were treated with LBH589 (10-
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25 nM) for a further 24 hours. At completion luciferase activity was assayed with a Luciferase 
Assay System (Promega Corporation, Madison, WI, USA). 
NIS immunofluorescence microscopy 
Cells (3 x 103) were seeded in 96-well plates. 24 hours after seeding cells were treated with 
LBH589 (25 and 50 nM) for 48 hours. After treatment cells were fixed in acetone/methanol (1:1) at 
-20 °C for 20 minutes, washed with PBS containing 0.5% Triton X-100, 0.05% NaN3 and 1% BSA 
and incubated overnight with monoclonal anti-NIS antibody (1:1000) (FP5A, Thermo Fisher 
Scientific, CA, USA) in PBS at 4°C. The cells were then washed three times with PBS containing 
0.5% Triton and 0.05% NaN3 for 10 minutes followed by detection with an anti-mouse Cy3-
conjugated secondary antibody (1:1000) (GE Healthcare Europe, GmbH, Milan, Italy) in PBS plus 
0.5% Triton and 0.05% NaN3 for 2 hours and the nuclei  were counterstained with Hoechst 33258 
(500 ng/ml in DMSO) in PBS. Cells were washed twice with distilled water and dried at 37°C. 
125I uptake and retention by cells 
Cells (2 x 104) were seeded in 24-well plates and incubated with LBH589 for 48 hours. 125I uptake 
was assayed as reported elsewhere (9). Briefly, after aspirating drug-containing medium, cells were 
washed with 1 ml HBSS (Invitrogen, Groningen, The Netherlands). 125I uptake was initiated by 
adding 0.5 ml HBSS containing 2 µCi carrier-free Na125I (PerkinElmer Life and Analytical 
Sciences, Inc., Boston, USA) and 30 µM NaI.  Samples were then incubated 30 min at 37°C.  At 
completion the radioactive medium was removed, the cells were then washed twice with ice-cold 
HBSS and solubilized with 1 ml of absolute ethanol for 20 min, after which cell-associated iodide 
was measured in a γ-counter (PerkinElmer Life and Analytical Sciences, Inc., Boston, USA).  To 
avoid any unspecific iodide uptake, control cells were pre-incubated with 300 µM KClO4 for 30 
min and then treated with 125I, as described above. 
Iodide efflux was studied by incubating cells for 30 min at 37°C in HBSS incubation buffer plus 2 
µCi carrier-free Na125I (PerkinElmer Life and Analytical Sciences, Inc., Boston, USA) and 30 µM 
NaI. The medium was then replaced every 5 min with fresh HBSS, for 30 minutes. Afterwards, 
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cells were solubilized with 1 ml absolute ethanol. Radioactivity was counted in both the medium 
and the cells. Total radioactivity at the beginning of the efflux (100%) was calculated by adding the 
radioactivity of all the media to those of the cells. The percentage of activity remaining in the cells 
at different times was obtained by subtracting the activity at each time from that of the total 
radioactivity at the beginning (16). 
Measured radioactivity was normalized by cell number and total activity in both the uptake and the 
efflux experiments. 
131I cytotoxicity 
1x102 cells were seeded into 24-well plates and left 48 hours to attach. 24 hours after treatment with 
25 nM LBH589, a clonogenic assay was performed. Briefly, drug-containing medium was 
discarded and cells were washed twice in PBS; the medium was then replaced with D-MEM-F12 
(Invitrogen, Groningen, The Netherlands) in the presence or absence of 20µCi 131I  (GE Healthcare 
S.r.l., Italy) for 6 hours. At the end of the treatment the radioactive medium was discarded, cells 
were washed and left in regular culture medium for the time corresponding to six doublings.  
Finally, cells that had formed colonies were fixed in methanol and stained with crystal violet. 
Control and 131I treated colonies were counted (17). 
Xenograft studies 
FFPE samples of tumors generated in SCID mice subcutaneously inoculated with CAL-62 cells and 
treated for 21 days with LBH589 (controls, n = 5; 20 mg/kg LBH589, n = 5), as described 
elsewhere (13), were assessed for the presence of NIS protein, using automated 
immunohistochemistry slide processing platforms (Ventana BenchMark AutoStainer, Ventana 
Medical Systems, Tucson, AZ, USA and Bond Max Leica, Germany) and a primary monoclonal 
antibody against human NIS (Clone FP5A Thermo Fisher Scientific, Fremont CA, USA). 
NIS was evaluated by one of the authors (SA) using the following semi-quantitative evaluation: 1) 
negative: no cells were stained; 2) positive: cells showed membrane, and/or sub-nuclear, and/or 
cytoplasm stain. 
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Statistical analysis 
Data are expressed throughout the text as means ± SD, calculated from at least three different 
experiments. Comparison between groups was performed with analysis of variance (one-way 
ANOVA) and the threshold of significance was calculated with the Bonferroni test. Statistical 
significance was set at p <0.05. 
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Results 
LBH589 effect on NIS expression  
To investigate the effect of LBH589 on NIS expression, we performed RT-PCR on both stabilized 
and primary cell cultures. In BHT-101 and CAL-62 cells, LBH589 stimulated NIS expression in a 
dose dependent-manner (Fig.1, panels A and B); these results were further confirmed by the 
activation of a NIS promoter luciferase construct in both cell lines (Fig.1, panels C and D). LBH589 
was also effective in inducing NIS expression in primary cell cultures, that did not express NIS in 
basal conditions (Table 1). In fact, we found NIS mRNA expression in all the cell lines treated with 
LBH589, albeit at different levels (Fig.3 panel A). As far as other thyroid related genes (i.e. TTF-1, 
Thyroglobulin, TSH-R and PAX8) are concerned, no modulation of the expression was observed 
(data not shown) after LBH589 treatment. 
NIS protein and function 
Immunofluorescence was performed on both stabilized cell lines and primary cultures to assess NIS 
protein expression. As shown in Fig.2, panels A and B, no NIS protein was present in either BHT-
101 or CAL-62 under basal conditions, but treatment with LBH589 induced the expression of the 
protein. This result was evident in all the primary cultures as shown in Fig. 3, panel B. NIS was 
correctly localized also on membranes of tumors treated with 25 nM LBH589 (5/5); all control 
cases were negative (0/5). A representative control case (panels A and B) and a treated tumor 
(panels C and D) are shown in Fig.4. 
125I uptake experiments confirmed not only the presence but also the function of the protein. In both 
stabilized cell lines we observed a dose dependent increase of iodide uptake (Fig.2, panel C and D). 
In primary cultures we chose a single concentration of 25 nM for the experiments of 125I uptake and 
we found 125I uptake restoration after LBH589 treatment in every cell culture (Fig.3, panel C). 
Iodine uptake was specifically dependent on NIS because it was blocked in response to treatment 
with KClO4, as shown in Fig.3 panel D. To evaluate the ability of ATC cells to retain iodide, we 
performed efflux studies, where the cells were repeatedly incubated with HBSS. As reported in 
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Fig.5, iodide retention was observed in both CAL-62 (83% retention after 5 min, t 1/2 = 19 min)  and 
CPa (79% retention after 5 min, t 1/2 = 17 min), suggesting that iodide is adequately retained by 
ATC cells after treatment with 25 nM LBH589.  
Iodide-induced  cytotoxicity 
Iodide uptake is not enough to deduce a possible cytotoxic effect of radioiodine on cells after 
LBH589 treatment. Therefore, to demonstrate radioiodine cytotoxic effects, a clonogenic assay with 
131I was performed in a stabilized cell line (CAL-62) and in a primary cell culture (CPa). As shown 
in Fig.6, we observed a reduction in LBH589-treated colonies forming cells after 131I treatment in 
both cell lines; in fact the number of colonies was significantly smaller in cells treated with 25 nM 
LBH589 compared to untreated controls (CAL-62: p <0.05; CPa p <0.01).  
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Discussion 
The absence of the sodium iodide symporter (NIS), along with other iodide-handling genes and 
specific thyroid transcription factors (18), characterizes anaplastic thyroid carcinomas, and results 
in resistance to radioiodine treatment. Since epigenetic modifications contribute to the silencing of 
thyroid-specific genes in advanced cancers, drugs modifying the epigenome are considered a 
promising tool to obtain a functional NIS (19). Recently it has been shown that global levels of 
acetylated histones are modified in thyroid cancer tissues and that lower levels of acetylated H3K18 
are associated with tumor progression (20). In the present study we demonstrate that LBH589 
induces NIS expression promoting the cytotoxic activity of radioiodine in anaplastic thyroid cancer.  
In fact, LBH589 induced NIS mRNA expression in a dose dependent manner in both stabilized cell 
lines and in all the primary cultures obtained from patients who underwent thyroidectomy for 
anaplastic thyroid cancer. The ability of other DCI to act on NIS expression in anaplastic thyroid 
cancer cells has already been reported (10, 21, 22). However, some previous studies showed the 
effect of DCI in ARO and /or BHP cells (10, 21), which are not of thyroid origin (23). The 
induction of NIS gene expression resulted in an increase in NIS protein expression, which was 
clearly demonstrated in all the cells we tested. In addition, in our in vivo model, NIS protein 
correctly localized on the membranes of tumors from LBH589-treated mice. Valproic acid as well 
as other drugs, such as 5’-Aza-2’-deoxycytydine and retinoic acid were able to restore NIS mRNA 
and protein expression in thyroid cancer cell lines, but this treatment was unable to restore protein 
function (9, 24).  
Here we also show that LBH589 activated NIS promoter in cells transfected with a construct 
containing the NIS promoter fused to luciferase. The NIS promoter can be activated by several 
thyroid-specific transcription factors (6,10). Even if various additional genes encoding tumor-
suppressors or proteins involved in thyroid hormone synthesis are epigenetically silenced in thyroid 
tumors (25, 26), we could not find a significant modulation of the expression of the other studied 
genes (TTF-1, TG, PAX8 and TSH-R) in any of the cell lines, consistent with other studies (10). The 
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observation that DCI modulate NIS expression in non-thyroid cells (that are not expressing thyroid-
restricted transcription factors) such as the human breast cancer cell line MCF-7 (10, 11), 
strengthens the concept that LBH589 may directly affect the NIS promoter, even though the 
established mechanism has not been investigated. 
We also demonstrated that LBH589 allowed iodide uptake and retention in both immortalized 
cultures of confirmed thyroid origin (23) and in primary cultures. The release of iodide that we 
observed was similar to that of cells stably expressing NIS (27, 28). Our data finally demonstrated 
that LBH589 was effective in inducing cytotoxic effects mediated by radioiodine in anaplastic 
thyroid cancer cells. The ability of LBH589 to express a functional symporter that allows 
radioiodine treatment appears extremely relevant and opens up therapeutic perspectives for 
undifferentiated thyroid tumors. 
Because of its rarity and rapidly fatal course, ATC is difficult to investigate at both the clinical and 
the experimental levels (29). Nevertheless, testing drugs on primary cultures may be considered an 
interesting way to design new strategies for chemo- and gene therapy (30), with the aim of 
increasing the effectiveness of treatment in each single patient. We were able to set up primary 
cultures for studying the effects of LBH589.  We constantly observed an increase in NIS 
expression, albeit at variable levels. These differences could be explained by a variable sensitivity 
to the drug due to the well-known heterogeneity of ATC. Moreover, the variability in iodide uptake 
in each primary culture is somehow similar to the great inter- and even intra-patient spectrum in 
radioiodine kinetics that are observed in patients treated with standard 131I doses (31). 
In conclusion, the present work suggests that histone deacetylase inhibitor LBH589 is an effective 
differentiating agent conferring to ATC cell lines and primary cultures radioiodine sensitivity. If 
confirmed, it provides a basis for clinical studies aimed at demonstrating an improvement of 
radioiodine uptake in patients with ATC.  
15 
 
 
Acknowledgments 
We thank Novartis Pharma AG, Basel, Switzerland for providing us with LBH589; Daniela 
Taverna and Francesca Orso, Dipartimento di Scienze Oncologiche, Universita` di Torino & M. B. 
C., Torino, Italy, for helping us with luciferase experiments. 
The study was supported by Fondazione CRT, Turin and by Regione Piemonte Grants to Giuseppe 
Boccuzzi.  
 
Author Disclosure Statement 
The authors have nothing to disclose. 
16 
 
References  
1. Fassnacht M, Kreissl, MC, Weismann D, Allolio B 2009 New targets and therapeutic 
approaches for endocrine malignancies. Pharmacol. Ther. 123:117-141.  
2. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC 2011 Anaplastic thyroid 
cancer: a review of epidemiology, pathogenesis, and treatment J Oncol. 2011:542358-
542371. 
3. Feinberg AP, Ohlsson R, Henikoff S 2006 The epigenetic progenitor origin of human cancer 
Nat Rev Genet. 7:21-33.  
4. Thaler F, Minucci S 2011 Next generation histone deacetylase inhibitors: the answer to the 
search for optimized epigenetic therapies?  Expert Opin. Drug Disc. 6:393-404.     
5. Smith VE, Read ML, Turnell AS, Watkins RJ, Watkinson JC, Lewy GD, Fong JC, James 
SR, Eggo MC, Boelaert K, Franklyn JA, McCabe CJ  2009 A novel mechanism of sodium 
iodide symporter repression in differentiated thyroid cancer J Cell Sci. 122:3393-3402.  
6. Kogai T, Taki K, Brent GA 2006 Enhancement of sodium/iodide symporter expression in 
thyroid and breast cancer Endocr Relat Cancer 13:797-826.  
7. Sherman SI 2010 Targeted therapy of thyroid cancer Biochem Pharmacol. 80:592-601.  
8. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH 
2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid 
cancer using Trichostatin A, a histone deacetylase inhibitor Surgery 132:984-990.  
9. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G 2004 Valproic 
acid induces the expression of the Na+/I- symporter and iodine uptake in poorly 
differentiated thyroid cancer cells J Clin Endocrinol Metab. 89:1006-1009.  
10. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi 
E, Mattei T, Pianta A, Pellizzari L, Damante G 2005 Effects of histone acetylation on 
sodium iodide symporter promoter and expression of thyroid-specific transcription factors 
Endocrinology 146:3967-3974.  
17 
 
11. Fortunati N, Catalano MG, Marano F, Mugoni V, Pugliese M, Bosco O, Mainini F, 
Boccuzzi G 2010 The pan-DAC inhibitor LBH589 is a multi-functional agent in breast 
cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS) Breast Cancer 
Res Treat. 124:667-675.  
12. Oki Y, Copeland A, Younes A 2011 Clinical development of panobinostat in classical 
Hodgkin's lymphoma Expert Rev Hematol. 4:245-52.  
13. Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, 
Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G 2012 Cytotoxic activity of 
the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro 
and in vivo Int J Cancer. 130:694-704.  
14. Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R, Asioli S, Bandino A, 
Palestini N, Grange C, Bussolati B, Boccuzzi G 2012 Histone deacetylaseinhibition 
modulates e-cadherin expression and suppresses migration and invasion of anaplastic 
thyroid cancer cells. J Clin Endocrinol Metab. 97:E1150-1159.  
15. Behr M, Schmitt TL, Espinoza CR, Loos U  1998 Cloning of a functional promoter of the 
human sodium/iodide-symporter gene. Biochem J 331:359–363.    
16. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, Traino C, Pacini F, Pinchera 
A 2006 Treatment with drugs able to reduce iodine efflux significantly increases the 
intracellular retention time in thyroid cancer cells stably transfected with sodium iodide 
symporter complementary deoxyribonucleic acid J Clin Endocrinol Metab 91(6):2389-2395.           
17. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C 2006 Clonogenic assay of 
cells in vitro Nat Protoc. 1:2315-2319.  
18. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, 
Kobayashi M, Katoh R 2009 Epigenetic silencing of TTF-1/NKX2–1 through DNA 
hypermethylation and histone H3 modulation in thyroid carcinomas Lab. Invest. 89:791–
799.  
18 
 
19. Russo D, Damante G, Puxeddu E, Durante C, Filetti S 2011 Epigenetics of thyroid cancer 
and novel therapeutic targets J Mol Endocrinol. 46:R73-81.  
20. Puppin C, Passon N, Lavarone E, Di Loreto C, Frasca F, Vella V, Vigneri R, Damante G 
2011 Levels of histone acetylation in thyroid tumors Biochem Biophys Res Commun. 
411:679-83.  
21. Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A, Bunce CM, Braunstein GD, 
Koeffler HP 2008 Induction of sodium iodide symporter gene and molecular 
characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid  cells. Br J Cancer 
99:781-788.  
22. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, 
Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in 
poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide 
symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.  
23. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, 
Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling 
analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell 
line redundancy and misidentification J Clin Endocrinol Metab 93:4331-4341. 
24. Vivaldi A, Miasaki FY, Ciampi R, Agate L, Collecchi P, Capodanno A, Pinchera A, Elisei R 
2009 Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine 
and retinoic acid  Mol Cell Endocrinol. 307:142-148.  
25. Kondo T, Asa SL, Ezzat S 2008 Epigenetic dysregulation in thyroid neoplasia Endocrinol 
Metab Clin North Am. 37:389-400.  
26. Xing M 2007 Gene methylation in thyroid tumorigenesis Endocrinology 148:948-953. 
27. Yoshida A, Taniguchi S, Hisatome I, Royaux IE, Green ED, Kohn LD, Suzuki K 2002 
Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J 
Clin Endocrinol Metab. 87(7):3356-3361. 
19 
 
28. Dingli D, Bergert ER, Bajzer Z, O'connor MK, Russell SJ, Morris JC 2004 Dynamic iodide 
trapping by tumor cells expressing the thyroidal sodium iodide symporter Biochem Biophys 
Res Commun. 325(1):157-66. 
29. Wiseman SM, Griffith OL, Gown A, Walker B, Jones SJ 2011 Immunophenotyping of 
thyroid tumors identifies molecular markers altered during transformation of differentiated 
into anaplastic carcinoma Am J Surg 201:580-586.  
30. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS 2009 Potential utility and 
limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 
19:1333-1342. 
31. Verburg FA, Brans B, Mottaghy F 2011 Molecular nuclear therapies for thyroid carcinoma 
Methods 55:230-237. 
 
20 
 
Figure Legends 
Figure 1. LBH589 effect on the expression of the NIS gene in BHT-101 (panel A) and CAL-62 
(panel B) cell lines. mRNA expression was evaluated with RT-PCR. Results are normalized for 
three different housekeeping genes (β-actin, β2-microglobulin and L13A) and expressed as relative 
expression fold vs lower level of expression (*, P<0.05; *** P<0.001). LBH589 effect on 
transcriptional activity of the NIS promoter in BHT-101 (panel C) and CAL-62 (panel D). Cells 
were transiently transfected with a reporter plasmid carrying the luciferase gene under the control of 
the promoter of NIS. The luciferase activity was assayed after LBH589 treatment; data are 
expressed as mean ± SD; n=3 Significance vs lower level of activity * P< 0.05 
Figure 2. LBH589 effect on NIS protein expression in BHT-101 (panel A) and CAL-62 (panel B) 
cell lines. Immunofluorescence for NIS was performed on cells in basal condition and after 
treatment with 25 and 50 nM LBH589. Magnification 400x. LBH589 effect on iodide uptake in 
BHT-101 (panel C) and CAL-62 (panel D) cell lines. 125I uptake in cells treated with 5-50 nM 
LBH589 was evaluated as described; data are expressed as mean ± SD; n=3. Significance vs 
untreated cells (0) was: *P<0.05; **P< 0.01; ***P< 0.001. 
Figure 3. LBH589 effect on NIS gene expression in primary cultures (panel A). mRNA 
expression was evaluated with RT-PCR. For each primary culture, results were first normalized for 
three different housekeeping genes (β-actin, β2-microglobulin and L13A),  and then expressed as 
relative expression fold vs CPS1 and 2 (normal controls for primary cultures). LBH589 effect on 
NIS protein expression in primary cultures (panel B). Immunofluorescence for NIS was 
performed on cells in basal conditions and after treatment with 25 nM LBH589. Magnification 
400x. LBH589 effect on iodide uptake in primary cultures. 125I uptake in cells treated with 25 nM 
LBH589 was evaluated as described; iodine uptake is expressed as relative expression fold vs CPS1 
and 2 (iodide uptake for CPS=47,000 cpm/106 cells ; for CPS2=43,000 cpm/106 cells). Data are 
expressed as mean ± SD; n=3 (panel C). 125I uptake in cells treated with KClO4 is expressed as 
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relative expression fold vs CPS1 and 2, and represented as mean ± SD of 125I uptake experiments of 
all the primary cultures (panel D). 
Figure 4. Immunohistochemistry of NIS in a sample from an untreated tumor xenograft (panel A: 
H&E; panel B: IHC) and in tumor xenograft treated with LBH589 (panel C: H&E; panel D: IHC).  
Panel B, inset: salivary gland tissue used as positive control. 
Figure 5. 125 Iodide retention in a stabilized cell line (CAL-62) and a primary culture (CPa) chosen 
as representative samples. Total radioactivity at the beginning of the efflux (100%) was calculated 
by adding the radioactivity of all media to those of the cells. The percentage of activity remaining in 
the cells at different times was obtained by subtracting the activity in each timed sample from that 
of the total radioactivity at the beginning. Results are normalized to total activity and cell number; 
experiments were performed in triplicate. 
Figure 6. LBH589 effect on 131I cytotoxicity. 131I cytotoxicity was evaluated through a colony 
forming assay as described; data are represented as number of colonies before ( 131I -) or after (131I 
+) the addition of 20 µM 131I to untreated cells (basal) or cells treated with 25 nM LBH589. Data 
are expressed as mean ± SD; n=3. A representative stabilized cell line (CAL-62, panel A) and a 
primary culture (CPa, panel B) are shown. Significance of cells treated with 25 nM LBH589 vs 
cells untreated with the deacetylase inhibitor: *p <0.05; **p < 0.01. 
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Table 1: Main characteristics of patients, original tissues and primary cultures 
Primary Cell Cultures Subjects Original Tissue 
  
Citokeratins Thyro globulin TTF1 NIS Age, yr Sex pTNM Histology Citokeratins 
Thyro 
globulin TTF1 NIS 
CPa Neg Neg Neg Neg 70 Female pT4a N0 M1 ATC Neg Neg Neg Neg 
CPb Neg Neg Neg Neg 58 Male pT4a N1b M0 ATC Neg Neg Neg Neg 
CPc Neg Neg Neg Neg 70 Male pT4a N0 M0 ATC Neg Neg Neg Neg 
CPd Neg Neg Neg Neg 65 Male pT4a N0 M0 ATC Neg Neg Neg Neg 
Cpe Neg Neg Neg Neg 58 Female pT4a N0 M1 ATC Neg Neg Neg Neg 
CPf Neg Neg Neg Neg 81 Female pT4a N1a M1 ATC Neg Neg Neg Neg 
CPg Neg Neg Neg Neg 59 Male pT4a N0 M0 ATC Neg Neg Neg Neg 
CPS1 Pos Pos Pos Pos 61 Female ------------- Normal  Pos Pos Pos Pos 
CPS2 Pos Pos Pos Pos 65 Male ------------- Normal Pos Pos Pos Pos 
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Table 2. Primers for real time PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primers 
TTF-1 Sense: 5’- CTC GCT CGC TCA CCC GTT GGC -3’ 
Antisense: 5’-GTC GTG TGC TTT GGA CTC ATC G -3’ 
PAX8 Sense: 5’- ATC AAT GGG CTC CTG GGC  ATC-3’ 
Antisense: 5’-GAG GTG GTG CTG GCT GAA GG -3’ 
TSH-R Sense: 5’- ACC CTG ATG CCC TCA AAG AGC-3’ 
Antisense: 5’- GCT TCA GTG TCA AGG TTT CAT TGC -3’ 
Thyroglobulin Sense: 5’- TCT AAC CGA TGC TCA CCT CTT CTG - 3’ 
Antisense: 5’- AGA TGA TGG CAC CTC CTT GAA CC - 3’ 
NIS Sense: 5'- CTG CCC CAG ACC AGT ACA TGC C -3' 
Antisense: 5'- TGA CGG TGA AGG AGC CCT GAA G -3' 
β-Actin Sense: 5’- GCG AGA AGA TGA CCC AGA TC- 3’ 
Antisense: 5’- GGA TAG CAC AGC CTG GAT AG-3’ 
β2-Microglobulin Sense: 5’-AGA TGA GTA TGC CTG CCG TGT G-3’ 
Antisense: 5’-TCA ACC CTC CAT GAT GCT GCT TAC-3’ 
L13A Sense: 5’-GCA AGC GGA TGA ACA CCA ACC-3’ 
Antisense: 5’-TTG AGG GCA GCA GGA ACC AC-3’ 
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